IDEAS home Printed from https://ideas.repec.org/a/sae/artjou/v18y2019i2p201-216.html
   My bibliography  Save this article

The Impact of Source of Funding on the Outcome of Clinical Trials in India

Author

Listed:
  • Benhur Ruqsana

Abstract

In recent times, there has been a surge of clinical trials in India. These trials are funded by different agents such as pharmaceutical industries, hospitals, research institutions, etc. Categorising the sponsors as pharmaceutical and non-pharmaceutical, this article tries to address the question whether the source of funding of the trials affects its outcome favourably. The study is carried out with 255 trials registered in Clinical Trials Registry-India from the year 2007 to 2009. Multivariate logistic regression analysis suggests that the trials conducted by pharmaceutical industries have significantly (at 10% level of significance) higher probability of success as compared to those sponsored by non-pharmaceutical industries. The possible reasons for this association are that trials conducted by pharmaceutical industries are in higher phase of study, use placebo as a control, are conducted in multiple centres and consist of large sample size. JEL: I11, C51

Suggested Citation

  • Benhur Ruqsana, 2019. "The Impact of Source of Funding on the Outcome of Clinical Trials in India," Arthaniti: Journal of Economic Theory and Practice, , vol. 18(2), pages 201-216, December.
    • Handle: RePEc:sae:artjou:v:18:y:2019:i:2:p:201-216
    DOI: 10.1177/0976747918795224
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0976747918795224
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0976747918795224?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Lewis Tracy R. & Reichman Jerome H. & So Anthony D., 2007. "The Case for Public Funding and Public Oversight of Clinical Trials," The Economists' Voice, De Gruyter, vol. 4(1), pages 1-4, January.
    2. Lisa Bero & Fieke Oostvogel & Peter Bacchetti & Kirby Lee, 2007. "Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others," PLOS Medicine, Public Library of Science, vol. 4(6), pages 1-10, June.
    3. Jayan Jose Thomas, 2008. "Innovation in India and China : Challenges and Prospects in Pharmaceuticals and Biotechnology," Development Economics Working Papers 22518, East Asian Bureau of Economic Research.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Antoine Popelut & Fabien Valet & Olivier Fromentin & Aurélie Thomas & Philippe Bouchard, 2010. "Relationship between Sponsorship and Failure Rate of Dental Implants: A Systematic Approach," PLOS ONE, Public Library of Science, vol. 5(4), pages 1-9, April.
    2. Ranjeet Kumar & R. C. Tripathi & M. D. Tiwari, 2011. "A case study of impact of patenting in the current developing economies in Asia," Scientometrics, Springer;Akadémiai Kiadó, vol. 88(2), pages 575-587, August.
    3. Younes, George Abi & Ayoubi, Charles & Ballester, Omar & Cristelli, Gabriele & de Rassenfosse, Gaetan & Foray, Dominique & Gaule, Patrick & van den Heuvel, Matthias & Webster, Beth & Zhou, Ling, 2020. "COVID-19: Insights from Innovation Economists (with French executive summary)," SocArXiv 65pgr, Center for Open Science.
    4. Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2009. "Trials, tricks and transparency: How disclosure rules affect clinical knowledge," Journal of Health Economics, Elsevier, vol. 28(6), pages 1141-1153, December.
    5. Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
    6. Dean Baker, 2008. "The Benefits and Savings of Publicly-Funded Clinical Trials of Prescription Drugs," CEPR Reports and Issue Briefs 2008-09, Center for Economic and Policy Research (CEPR).
    7. Younes, George Abi & Ayoubi, Charles & Ballester, Omar & Cristelli, Gabriele & de Rassenfosse, Gaetan & Foray, Dominique & Gaule, Patrick & Pellegrino, Gabriele & van den Heuvel, Matthias & Webster, B, 2020. "COVID-19_Insights from Innovation Economists," SocArXiv b5zae, Center for Open Science.
      • Dominique Foray & Gaetan de Rassenfosse & George Abi Younes & Charles Ayoubi & Omar Ballester & Gabriele Cristelli & Matthias van den Heuvel & Ling Zhou & Gabriele Pellegrino & Patrick Gaulé & Elizab, 2020. "COVID-19: Insights from Innovation Economists," Working Papers 10, Chair of Science, Technology, and Innovation Policy.
    8. Daniel M Cook & Elizabeth A Boyd & Claudia Grossmann & Lisa A Bero, 2007. "Reporting Science and Conflicts of Interest in the Lay Press," PLOS ONE, Public Library of Science, vol. 2(12), pages 1-5, December.
    9. Anna Lene Seidler & Kylie E Hunter & Nicholas Chartres & Lisa M Askie, 2019. "Associations between industry involvement and study characteristics at the time of trial registration in biomedical research," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-12, September.
    10. Ferrán Catalá-López & Gabriel Sanfélix-Gimeno & Manuel Ridao & Salvador Peiró, 2013. "When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins," PLOS ONE, Public Library of Science, vol. 8(7), pages 1-1, July.
    11. Lexchin, Joel & O'Donovan, Orla, 2010. "Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies," Social Science & Medicine, Elsevier, vol. 70(5), pages 643-647, March.
    12. David Krauth & Andrew Anglemyer & Rose Philipps & Lisa Bero, 2014. "Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis," PLOS Biology, Public Library of Science, vol. 12(1), pages 1-10, January.
    13. Ferrán Catalá-López & Adolfo Alonso-Arroyo & Rafael Aleixandre-Benavent & Manuel Ridao & Máxima Bolaños & Anna García-Altés & Gabriel Sanfélix-Gimeno & Salvador Peiró, 2012. "Coauthorship and Institutional Collaborations on Cost-Effectiveness Analyses: A Systematic Network Analysis," PLOS ONE, Public Library of Science, vol. 7(5), pages 1-9, May.
    14. Rima Nakkash & Ahmed Ali & Hala Alaouie & Khalil Asmar & Norbert Hirschhorn & Sanaa Mugharbil & Iman Nuwayhid & Leslie London & Amina Saban & Sabina Faiz Rashid & Md Koushik Ahmed & Cecile Knai & Char, 2020. "Attitudes and practices of public health academics towards research funding from for-profit organizations: cross-sectional survey," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 65(7), pages 1133-1145, September.

    More about this item

    Keywords

    Clinical trials; pharmaceutical industries; Clinical Trials Registry-India (CTRI); outcomes; source of funding;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • C51 - Mathematical and Quantitative Methods - - Econometric Modeling - - - Model Construction and Estimation

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:artjou:v:18:y:2019:i:2:p:201-216. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.